The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...
The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback